Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.45 |
| ▸ | NOS1 | P29475 | 3/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5892305 | 0.83 | MAOB (0.44) | IDO1NOS1NOS3NOS2MAOB | |
| SCHEMBL7521191 | 0.82 | NOS1 (0.47) | IDO1NOS1NOS3NOS2MAOB | |
| SCHEMBL5783496 | 0.77 | MAOB (0.46) | MAOBCA1CA2ARG2 | |
| Allylbenzene SCHEMBL27371382 | 0.74 | KDM4E (0.40) | IDO1NOS1NOS3NOS2MAOB | |
| SCHEMBL4960106 | 0.74 | F2 (0.41) | IDO1NOS1NOS3NOS2GRIN2D | |
| SCHEMBL1524905 | 0.73 | ALDH1A1 (0.44) | MAOB | |
| SCHEMBL630686 | 0.72 | POLB (0.42) | IDO1NOS1NOS3NOS2 | |
| SCHEMBL8457012 | 0.72 | NPC1 (0.51) | IDO1CA1 | |
| SCHEMBL10585859 | 0.72 | MEN1 (0.57) | — | |
| SCHEMBL6703435 | 0.71 | NOS1 (0.52) | IDO1NOS1NOS3NOS2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024000-A1 | Dihydropyrimidine derivatives as cysteine protease inhibitors | NAEJA PHARMACEUTICAL INC. (CA) | 2004-02-05 | — | — | US | claimed |
| EP-1326848-A1 | DIHYDROPYRIMIDINE DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | Naeja Pharmaceutical Inc. (CA) | 2003-07-16 | — | — | EP | claimed |
| WO-2002032879-A1 | DIHYDROPYRIMIDINE DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2002-04-25 | — | — | WO | claimed |
| US-20040024000-A1 | Dihydropyrimidine derivatives as cysteine protease inhibitors | NAEJA PHARMACEUTICAL INC. (CA) | 2004-02-05 | — | — | US | disclosed |
| EP-1326848-A1 | DIHYDROPYRIMIDINE DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | Naeja Pharmaceutical Inc. (CA) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002032879-A1 | DIHYDROPYRIMIDINE DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024000-A1 | Dihydropyrimidine derivatives as cysteine protease inhibitors | DPEP1, DNPEP, PEPD | IDO1 1892/4885NOS1 4287/4885NOS3 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.